Biopharma company Ipsen invests €52m in Blanchardstown site upgrade

  • 📰 IrishTimesBiz
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 77%

United States News News

United States United States Latest News,United States United States Headlines

Paris-headquartered multinational has increased production at the west Dublin manufacturing facility by 10% this year via IrishTimesBiz

Ipsen plans to invest a further €15 million in its Blanchardstown site between 2023 and 2026, it said. The company has expanded its workforce at the facility by 20 per cent since 2019 and is focused on driving continued research and innovation through its R&D division, having grown its team of chemists and analysts by 10 per cent over the past two years.

“It’s great to see a biopharmaceutical company which has been here for over 30 years continuing to invest and grow in Ireland, particularly when the goal is to help more patients achieve a better quality of life through its medicines,” said Mr Varadkar, as he welcomed the site launch and investment announcement.

“We hope to continue building Ipsen Ireland as an important pharmaceutical manufacturing and development site within Europe. Now we welcome the continued efforts of the Irish Government to invest in the innovative medicines that will enable Ipsen Ireland to transform even more patients’ lives.”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in US

United States United States Latest News, United States United States Headlines